Human Embryonic Stem Cells and Their Differentiated Derivatives Are Less Susceptible to Immune Rejection Than Adult Cells
The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Abstract
Differentiated cell types derived from human embryonic stem cells (hESCs) may serve in the future to treat various human diseases. A crucial step toward their successful clinical application is to examine the immune response that might be launched against them after transplantation. We used two experimental platforms to examine the in vivo leukocyte response toward hESCs. First, immunocompetent and immunodeficient mouse strains were used to identify T cells as the major component that causes xenorejection of hESCs. Second, mice that were conditioned to carry peripheral blood leukocytes from human origin were used to test the human leukocyte alloresponse toward undifferentiated and differentiated hESCs. Using this model, we have detected only a minute immune response toward undifferentiated as well as differentiated hESCs over the course of 1 month, although control adult grafts were repeatedly infiltrated with lymphocytes and destroyed. Our data show that the cells evade immune destruction due to a low immunostimulatory potential. Nevertheless, a human cytotoxic T lymphocyte clone that was specifically prepared to recognize two hESC lines could lyse the cells after major histocompatibility complex class I (MHC-I) induction. Although MHC-I levels in hESCs are sufficient for rejection by cytotoxic T cells, our data suggest that the immunostimulatory capacity of the cells is very low. Thus, immunosuppressive regimens for hESC-based therapeutics could be highly reduced compared with conventional organ transplantation because direct allorejection processes of hESCs and their derivatives are considerably weaker.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although most of the pluripotent stem cells have low HLA expression [93], iPSC derivatives can trigger an immune response.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [93]
Citations
Cites
Embryonic Stem Cell Lines Derived from Human Blastocysts
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998) · Science · doi:10.1126/science.282.5391.1145 · Cited by 15,926
Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro
Reubinoff, B. E., Pera, M. F., Fong, C.-Y., Trounson, A., & Bongso, A. (2000) · Nature Biotechnology · doi:10.1038/74447 · Cited by 2,706
In vitro differentiation of transplantable neural precursors from human embryonic stem cells
Zhang, S.-C., Wernig, M., Duncan, I. D., Brüstle, O., & Thomson, J. A. (2001) · Nature Biotechnology · doi:10.1038/nbt1201-1129 · Cited by 1,912
Kehat, I., Kenyagin‐Karsenti, D., Snir, M., Segev, H., Amit, M., Gepstein, A., Livne, E., Binah, O., Itskovitz‐Eldor, J., & Gepstein, L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12131 · Cited by 1,814
Sharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712
Kehat, I., Kenyagin‐Karsenti, D., Snir, M., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200112131 · Cited by 1,536
Itskovitz-Eldor, J., Schuldiner, M., Karsenti, D., Eden, A., Yanuka, O., Amit, M., Soreq, H., & Benvenisty, N. (2000) · Molecular Medicine · doi:10.1007/bf03401776 · Cited by 1,500
Self-citationPrognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Schuldiner, M., Yanuka, O., Itskovitz-Eldor, J., Melton, D. A., & Benvenisty, N. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.21.11307 · Cited by 1,134
Self-citationNeural progenitors from human embryonic stem cells
Reubinoff, B. E., Itsykson, P., Turetsky, T., Pera, M. F., Reinhartz, E., Itzik, A., & Ben-Hur, T. (2001) · Nature Biotechnology · doi:10.1038/nbt1201-1134 · Cited by 1,119
Cited by
Items 101–200 of 403
Kruse, V., Hamann, C., Monecke, S., Cyganek, L., Elsner, L., Hübscher, D., Walter, L., Streckfuss-Bömeke, K., Guan, K., & Dressel, R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125544 · Cited by 57
“In mice, several immune effector mechanisms appear to be important for the rejection of pluripotent stem cell-derived teratomas in allogeneic hosts, including T cells [10, 11] and the complement system [12].”
BackgroundDressel, R. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0266-8 · Cited by 66
“Transplantation of mouse and human ESCs into immunocompetent xenogeneic murine hosts usually does not lead to teratomas [61, 67, 73, 77] suggesting the rejection of xenogeneic stem cells or their derivatives formed in vivo by the recipient’s immune system.”
BackgroundInfluentialStargardt disease and progress in therapeutic strategies
Huang, D., Jeffery, R. C. H., Aung-Htut, M. T., McLenachan, S., Fletcher, S., Wilton, S. D., & Chen, F. K. (2021) · Ophthalmic Genetics · doi:10.1080/13816810.2021.1966053 · Cited by 58
Human embryonic stem cells for cardiomyogenesis
Habib, M., Caspi, O., & Gepstein, L. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.08.008 · Cited by 62
“Moreover, using the human/mouse trimera model (enabling the assessment of the direct allo-immune response of human immune system to transplanted human cells) it was demonstrated that transplanted hESC elicit only a relatively small immune response [88].”
MethodFrenzel, L. P., Abdullah, Z., Kriegeskorte, A. K., Dieterich, R., Lange, N., Busch, D. H., Krönke, M., Utermöhlen, O., Hescheler, J., & Šarić, T. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0528 · Cited by 57
Ali, I., Padhiar, A. A., Wang, T., He, L., Chen, M., Wu, S., Zhou, Y., & Zhou, G. (2022) · Cells · doi:10.3390/cells11233713 · Cited by 57
Chan, K., Bonde, S., Klump, H., & Zavazava, N. (2007) · Blood · doi:10.1182/blood-2007-10-117366 · Cited by 55
The immune boundaries for stem cell based therapies: problems and prospective solutions
Hmadcha, A., Juan, D., Wakeman, J. A., Mohamed, A., & Soria, B. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00837.x · Cited by 58
“In contrast to the expression of class I antigens, however, hESCs do not express HLA class II, nor the costimulatory molecules, such as CD80 and CD86 [128].”
BackgroundAnderson, J. S., Bandi, S., Kaufman, D. S., & Akkina, R. (2006) · Retrovirology · doi:10.1186/1742-4690-3-24 · Cited by 60
“However, a recent study using human leukocyte reconstituted mice suggested that hESCs and their derivative cell types were less prone to invoking an allogeneic response [ 53 ].”
BackgroundSerpin-6 Expression Protects Embryonic Stem Cells from Lysis by Antigen-Specific CTL
Abdullah, Z., Šarić, T., Kashkar, H., Baschuk, N., Yazdanpanah, B., Fleischmann, B. K., Hescheler, J., Krönke, M., & Utermöhlen, O. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3390 · Cited by 56
Liu, K.-J., Wang, C.-J., Chang, C.-J., Hu, H.-I., Hsu, P., Wu, Y.-C., Bai, C., Sytwu, H., & Yen, B. L. (2011) · Cell Transplantation · doi:10.3727/096368911x580590 · Cited by 53
Banerjee, S., & Bacanamwo, M. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.08.011 · Cited by 58
“ESC are a better source of endothelial cells compared with other endothelial cell origins, due to their low immunogenicity [9], high proliferation potential, and”
BackgroundHickson, L. J., Abedalqader, T., Ben-Bernard, G., Mondy, J., Bian, X., Conley, S. M., Zhu, X., Herrmann, S. M., Kukla, A., Lorenz, E. C., et al. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0419 · Cited by 55
Immunologic and Inflammatory Reactions to Exogenous Stem Cells
Buja, L. M., & Vela, D. C. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.041 · Cited by 52
Kim, A., Yu, H. Y., Lim, J., Ryu, C., Kim, Y. H., Heo, J., Han, J., Lee, S., Bae, Y. S., Kim, J. Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09330-x · Cited by 55
Romano, S., Tufano, M., D’Arrigo, P., Vigorito, V., Russo, S., & Romano, M. F. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.015 · Cited by 54
Human embryonic stem cells: Possibilities for human cell transplantation
Liew, C.-G., Moore, H. D. M., Ruban, L., Shah, N., Cosgrove, K. E., Dunne, M. J., & Andrews, P. W. (2005) · Annals of Medicine · doi:10.1080/07853890500379463 · Cited by 56
“Interestingly, recent evidence suggests that human ES cells and their derivatives are much less susceptible to immune rejection than adult cells and they did not elicit direct allorejection in vivo (90).”
BackgroundImmunological properties of embryonic and adult stem cells
Bifari, F., Pacelli, L., & Krampera, M. (2010) · World Journal of Stem Cells · doi:10.4252/wjsc.v2.i3.50 · Cited by 54
Induced Pluripotent Stem Cell-Based Cancer Vaccines
Ouyang, X., Telli, M. L., & Wu, J. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01510 · Cited by 57
“ESCs express low levels of HLA class I molecules (45) and almost undetectable levels of HLA class II and costimulatory molecules (46).”
BackgroundEquine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro
Paterson, Y. Z., Rash, N. L., Garvican, E. R., Paillot, R., & Guest, D. J. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt479 · Cited by 57
“It has been suggested that low MHC expression results in a reduction of stimulatory signals to aid in evasion of an immune attack [22,24], forming an additional or alternate mechanism by which MSCs and ESCs were able to avoid stimulation of a proliferative response in PBMCs.”
BackgroundResultNonclinical safety strategies for stem cell therapies
Sharpe, M. E., Morton, D. G., & Rossi, A. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.05.007 · Cited by 51
Kim, J. M., Hong, K., Song, W. K., Bae, D., Hwang, I.-K., Kim, J. S., & Chung, H. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0342 · Cited by 49
Chang, H.-T., Heuer, R. A., Oleksijew, A. M., Coots, K. S., Roque, C. B., Nella, K. T., McGuire, T. L., & Matsuoka, A. J. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.03.007 · Cited by 49
“Second, hESCs lack co-stimulatory molecules, such as CD 80 and CD 86, which are essential for attacking transplanted hESCs in immunorejection responses [105].”
Dong, W., Du, J., Shen, H., Gao, D., Li, Z., Wang, G., Mu, X., & Liu, Q. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0899-9 · Cited by 48
“Recently, it has been shown that expression of MHC class I molecules on ESCs is suYcient to induce recognition and rejection by cytotoxic T lymphocytes [ 35 ].”
BackgroundImmunological Barriers to Embryonic Stem Cell-Derived Therapies
Šarić, T., Frenzel, L. P., & Hescheler, J. (2008) · Cells Tissues Organs · doi:10.1159/000118784 · Cited by 50
“Similarly, in vitro generated alloreactive CTLs were not cytolytic against unstimulated murine ES cells, but were able to slightly lyse only the IFN- -treated ES cells [Fabricius et al., 2005; Bonde and Zavazava, 2006].”
BackgroundResultInfluentialHarkness, L., Mahmood, A., Ditzel, N., Abdallah, B. M., Nygaard, J. V., & Kassem, M. S. (2010) · Bone · doi:10.1016/j.bone.2010.09.023 · Cited by 48
“[47] reported that, due to low expression levels of MHC class-I and the absence of MHC class-II molecules, immunostimulatory response of hESC and their differentiated derivatives is low suggesting a lesser degree of immune suppression is required when cell therapy protocols are initiated.”
Lai, L., Cui, C., Jin, J., Hao, Z., Zheng, Q., Ying, M., Boyd, R. L., & Zhao, Y. X. (2011) · Blood · doi:10.1182/blood-2011-03-340794 · Cited by 49
Furth, M. E., & Atala, A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398358-9.00006-9 · Cited by 55
Lee, J. E., Kang, M. S., Park, M. H., Shim, S. H., Yoon, T. K., Chung, H., & Lee, D. R. (2010) · Cell Transplantation · doi:10.3727/096368910x513991 · Cited by 47
Embryonic Stem Cell Transplantation: Promise and Progress in the Treatment of Heart Disease
Zhang, F., & Pasumarthi, K. B. S. (2008) · BioDrugs · doi:10.2165/0063030-200822060-00003 · Cited by 49
Stem cell-based cell replacement strategies for the central nervous system
Sharp, J., & Keirstead, H. S. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2008.04.106 · Cited by 47
Concise Review: The Potential of Stem Cells for Auditory Neuron Generation and Replacement
Nayagam, B. A., Silva, M. D., & Shepherd, R. K. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0393 · Cited by 46
Grinnemo, K., Genead, R., Kumagai‐Braesch, M., Andersson, A., Danielsson, C., Månsson‐Broberg, A., Dellgren, G., Strömberg, A., Ekberg, H., Hovatta, O., et al. (2008) · Stem Cells · doi:10.1634/stemcells.2008.0111 · Cited by 43
Can Mesenchymal Stem Cells Induce Tolerance to Cotransplanted Human Embryonic Stem Cells?
Puymirat, É., Geha, R., Tomescot, A., Bellamy, V., Larghero, J., Trinquart, L., Bruneval, P., Desnos, M., Hagège, A. A., Pucéat, M., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.208 · Cited by 43
Immunogenicity and Allogenicity: A Challenge of Stem Cell Therapy
Charron, D. J., Suberbielle, C., & Al‐Daccak, R. (2008) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-008-9062-9 · Cited by 42
“The concept that ESC may harbor measures of immune privilege has gained support from trima mouse model of ESC transplantation where human embryonic stem cells (hESC) were administrated under the kidney capsule of recipients reconstituted with human peripheral blood leukocytes [ 6 ].”
MethodImmunobiology of naïve and genetically modified HLA-class-I-knockdown human embryonic stem cells
Deuse, T., Seifert, M., Phillips, N., Fire, A. Z., Tyan, D. B., Kay, M. A., Tsao, P. S., Hua, X., Velden, J., EIERMANN, T. H., et al. (2011) · Journal of Cell Science · doi:10.1242/jcs.087718 · Cited by 44
“J o u rn a l o f C e ll S c ie n c e Hsp70-expressing MICA-positive human tumors (Elsner et al., 2007).”
BackgroundZheng, D., Wang, X., & Xu, R. (2016) · Stem Cells · doi:10.1002/stem.2407 · Cited by 45
Jiang, H., Zhang, Y., Tian, K.-W., Wang, B., & Han, S. (2017) · Scientific Reports · doi:10.1038/srep41837 · Cited by 42
“MSCs transplantation has emerged as an attractive therapy for MS due to ease of expansion and immunomodulatory and neuroprotective effects of MSCs, and demonstrated fewer side effects than other therapies 12,13 .”
Stem cells used for cardiovascular tissue engineering☆
Siepe, M., Akhyari, P., Lichtenberg, A., Schlensak, C., & Beyersdorf, F. (2008) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2008.03.067 · Cited by 49
Chen, H., Yu, C., Chen, M., Chou, S.-H., Chiang, M.-S., Chou, W.-H., Ko, B., Huang, H., Kuo, H., & Ho, H. (2013) · Cell Transplantation · doi:10.3727/096368913x674639 · Cited by 41
Roadblocks en route to the clinical application of induced pluripotent stem cells
Lowry, W. E., & Quan, W. L. (2010) · Journal of Cell Science · doi:10.1242/jcs.054304 · Cited by 43
“…the differentiation state of a stem-cell population is related to the strength of the immune response that is induced following transplantation (Drukker et al., 2006; Magliocca et al., 2006; Swijnenburg et al., 2008), although it is generally thought that less differentiated cells induce a…”
BackgroundProgress and prospects: gene transfer into embryonic stem cells
Yates, F., & Daley, G. Q. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302854 · Cited by 44
Daadi, M. M., & Steinberg, G. K. (2009) · Regenerative Medicine · doi:10.2217/17460751.4.2.251 · Cited by 41
Cai, J., Yi, F.-F., Yang, X., Lin, G.-S., Jiang, H., Wang, T., & Xia, Z. (2007) · Cytotherapy · doi:10.1080/14653240701247838 · Cited by 40
Belegu, V., Oudega, M., Gary, D. S., & McDonald, J. W. (2007) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2006.10.012 · Cited by 42
Allogenic benefit in stem cell therapy: cardiac repair and regeneration
Al‐Daccak, R., & Charron, D. J. (2015) · Tissue Antigens · doi:10.1111/tan.12614 · Cited by 38
D’Addio, F., Trevisani, A., Nasr, M. B., Bassi, R., Essawy, B. E., Abdi, R., Secchi, A., & Fiorina, P. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0603-1 · Cited by 37
“Despite the lack of experimental evidence regarding the possible use of embryonic stem cells (ESCs) in DN, ESCs appear to be immunoprivileged and possess immunoregulatory properties when examined in alloimmune settings [42, 43].”
BackgroundDeuse, T., Seifert, M., Phillips, N., Fire, A. Z., Tyan, D. B., Kay, M. A., Tsao, P. S., Hua, X., Velden, J., EIERMANN, T. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.020727 · Cited by 36
Kim, E., Manzar, G. S., & Zavazava, N. (2013) · Blood · doi:10.1182/blood-2012-11-467753 · Cited by 37
“Moreover, several groups have reported that embryonic stem cells (ESCs) are poorly immunogenic due to their low expression of classical major histocompatibility complex (MHC) I and lack of MHC-II antigens.(7,8) Our group recently successfully established mixed chimerism in mice transplanted with mouse ESCderived hemat…”
BackgroundA review and update on the current status of stem cell therapy and the retina
Ong, J. M., & da Cruz, L. (2012) · British Medical Bulletin · doi:10.1093/bmb/lds013 · Cited by 38
Petrash, C. C., Palestine, A. G., & Canto-Soler, M. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.621007 · Cited by 38
“In addition, both stem cells and RPE are attributed with antiinflammatory properties that enhance compatibility (13, 14).”
BackgroundImmunogenicity of Embryonic Stem Cells and Their Progeny
Drukker, M. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(06)20019-3 · Cited by 39
Self-citationZeng, Q., Macri, L. K., Prasad, A., Clark, R. A. F., Zeugolis, D. I., Hanley, C., Garcia, Y., & Pandit, A. S. (2011) · Elsevier eBooks · doi:10.1016/b978-0-08-055294-1.00186-0 · Cited by 43
Therapeutic Potentials of Human Embryonic Stem Cells in Parkinson’s Disease
Newman, M. B., & Bakay, R. A. E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.02.004 · Cited by 37
Tang, C. Z., & Drukker, M. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0269-5 · Cited by 36
“We [2, 37] and others [38–40] have found that MHC-I molecules are expressed on pluripotent human ESCs and their differentiated derivatives, albeit at levels considerably lower than somatic cells.”
MethodResultSelf-citationA Systematic Review on Transplantation Studies of the Retinal Pigment Epithelium in Animal Models
Koster, C., Wever, K. E., Wagstaff, E. L., van den Hurk, K., Hooijmans, C. R., & Bergen, A. A. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082719 · Cited by 37
“Embryonic stem cell (ESC)-RPE cells or HLA-typed iPSCs can act as universal donors for large (sub-) populations since these cells are generally less immunogenic [79].”
BackgroundDrukker, M. (2007) · Seminars in Immunology · doi:10.1016/j.smim.2007.11.002 · Cited by 36
“Together with colleagues, we have recently shown that hESCs and differentiated derivatives have a very low co-stimulatory potential, as they do not express these molecules [ 13 ].”
BackgroundSelf-citationEstimating human embryonic stem-cell numbers
Rao, M. S., & Auerbach, J. M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68261-5 · Cited by 33
Prowse, A. B. J., Timmins, N. E., Yau, T. M., Li, R., Weisel, R. D., Keller, G. M., & Zandstra, P. W. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.08.005 · Cited by 34
Myocardial regeneration strategies using human embryonic stem cell-derived cardiomyocytes
Capi, O., & Gepstein, L. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.06.027 · Cited by 32
Mohib, K., Allan, D., & Wang, L. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9185-7 · Cited by 35
“However, studies carried out with hESCs have ruled out FasL as a causative factor [17].”
BackgroundInfluentialCampagnolo, P., Tsai, T.-N., Hong, X., Kirton, J. P., So, P., Margariti, A., Bernardini, E. D., Wong, M. M., Hu, Y., Stevens, M. M., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.04.055 · Cited by 31
Xie, C., Zhang, J., Xiao, Y., Zhang, L., Mou, Y., Liu, X., Akinbami, M. A., Cui, T., & Chen, Y. E. (2007) · Stem Cells and Development · doi:10.1089/scd.2006.110206 · Cited by 31
“Although cardiomyocytes derived from human embryonic stem (hES) cells have been documented to integrate efficiently into of the hearts of host animals (3,6,7,8), the”
BackgroundBrunlid, G., Pruszak, J., Holmes, B., Ole Isacson, A., & Sonntag, K. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0745 · Cited by 30
He, Q., Trindade, P. T., Stumm, M., Li, J., Zammaretti, P., Bettiol, E., Dubois‐Dauphin, M., Herrmann, F. R., Kalangos, A., Morel, D. R., et al. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00323.x · Cited by 29
Calderon, D., Planat‐Benard, V., Bellamy, V., Vanneaux, V., Kuhn, C., Peyrard, S., Larghero, J., Desnos, M., Casteilla, L., Pucéat, M., et al. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01435.x · Cited by 28
Sackett, S. D., Brown, M. E., Tremmel, D. M., Ellis, T. M., Burlingham, W. J., & Odorico, J. S. (2016) · Transplantation Reviews · doi:10.1016/j.trre.2016.02.001 · Cited by 30
Embryonic stem cells: protecting pluripotency from alloreactivity
Fairchild, P. J., Robertson, N. J., Minger, S. L., & Waldmann, H. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.07.010 · Cited by 28
Cegielski, M., Dziewiszek, W., Zabel, M., Dzięgiel, P., Iżycki, D., Zatoński, M., & Bochnia, M. (2008) · Xenotransplantation · doi:10.1111/j.1399-3089.2008.00497.x · Cited by 27
“[52] suggest that, in fetal live, human stem cells develop immunospecificity antigens very late and therefore allogeneic implants are not rejected.”
BackgroundImmunoregulatory Properties of Mouse Limbal Stem Cells
Holáň, V., Pokorná, K., Procházková, J., Krulová, M., & Zajícová, A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903049 · Cited by 27
Immunological Barriers to Stem-Cell Based Cardiac Repair
Karabekian, Z. I., Posnack, N. G., & Sarvazyan, N. A. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9202-x · Cited by 27
“The discrepancies between the above cited studies [61, 70, 74, 86, 87] in the detection/expression of FasL on the surface of PSC and their derivatives can be explained by many factors.”
BackgroundInfluentialAvoiding Immunological Rejection in Regenerative Medicine
Bolton, E. M., & Bradley, J. A. (2015) · Regenerative Medicine · doi:10.2217/rme.15.11 · Cited by 27
Equivalence of Conventionally-Derived and Parthenote-Derived Human Embryonic Stem Cells
Harness, J. V., Turovets, N., Seiler, M. J., Nistor, G., Altun, G., Agapova, L. S., Ferguson, D. J. P., Laurent, L. C., Loring, J. F., & Keirstead, H. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014499 · Cited by 26
“hESCs express no human leukocyte antigen (HLA)-DR, DP, DQ and only low levels of HLA-A, B, C even when exposed to pro-inflammatory cytokines [16,22,23], but it is not yet clear how differentiated cells would be tolerated long-term.”
BackgroundApproaches for immunological tolerance induction to stem cell-derived cell replacement therapies
Boyd, A. S., & Fairchild, P. J. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.20 · Cited by 28
Velasquez-Mao, A. J., Tsao, C., Monroe, M. N., Legras, X. D., Bissig-Choisat, B., Bissig, K., Ruano, R., & Jacot, J. G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177824 · Cited by 28
Human embryonic stem cells hemangioblast express HLA-antigens
Basak, G. W., Yasukawa, S., Alfaro, A., Halligan, S., Srivastava, A., Min, W., Minev, B., & Carrier, E. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-27 · Cited by 28
Tabayoyong, W., Salas, J. G., Bonde, S., & Zavazava, N. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901807 · Cited by 25
“In support of this idea, in vivo studies using a humanized mouse model to characterize the immunogenicity of human ES cells and EB cells demonstrated that human ES cells and their EB derivatives induced considerably weaker allogeneic immune responses than adult allografts (12).”
BackgroundResultThe art of cobbling a running pump—Will human embryonic stem cells mend broken hearts?
Zweigerdt, R. (2007) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2007.09.014 · Cited by 26
Negligible Immunogenicity of Induced Pluripotent Stem Cells Derived from Human Skin Fibroblasts
Lu, Q., Yu, M., Shen, C., Chen, X., Feng, T., Yao, Y., Li, J., Li, H., & Tu, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114949 · Cited by 25
“immunogenicity of ESCs results from low expression of MHC-I and negative MHC-II, costimulatory molecules [25, 27, 28].”
BackgroundLuo, J., Weaver, M. S., Cao, B., Dennis, J. E., Biber, B. P. V., Laflamme, M. A., & Allen, M. D. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2013-0189 · Cited by 25
Derivation of Human Embryonic Stem Cells in Xeno-Free Conditions
Vemuri, M. C., Schimmel, T., Colls, P., Munné, S., & Cohen, J. (2007) · Methods in molecular biology · doi:10.1007/978-1-59745-536-7_1 · Cited by 25
In vitro immunogenicity of undifferentiated pluripotent stem cells (PSC) and derived lineages
Kadereit, S., & Trounson, A. O. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0265-9 · Cited by 26
“immune suppression [32].”
BackgroundInfluentialImmune regulation by non-lymphoid cells in transplantation
Dugast, A., & Vanhove, B. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03877.x · Cited by 29
MFG-E8 Is Critical for Embryonic Stem Cell-Mediated T Cell Immunomodulation
Tan, Y., Al-Khamees, B., Jia, D., Li, L., Couture, J., Figeys, D., Jinushi, M., & Wang, L. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.09.005 · Cited by 24
“Nuclei were counterstained with DAPI (blue). immunogenic (Fairchild et al., 2007).”
Recent Findings on Therapeutic Cancer Vaccines: An Updated Review
Sheikhlary, S., Lopez, D. H., Moghimi, S., & Sun, B. (2024) · Biomolecules · doi:10.3390/biom14040503 · Cited by 26
“Although Although ESCs express a low amount of HLA-I [159–163] and almost no HLA-II [162–165] and costimulatory molecules [162,164,165], this amount is sufficient to stimulate the cytotoxic T cell-mediated xenorejection of human ESCs [158,166,167].”
BackgroundFrederiksen, H. R. S., Doehn, U., Tveden‐Nyborg, P., & Freude, K. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.623717 · Cited by 24
“…specific cell types such as glutamatergic and GABAergic neurons, astrocytes, oligodendrocytes and microglia from hiPSC have been greatly improved over the past decade, allowing the investigation of cell type specific disease mechanisms caused by the pathogenic mutations (Ebert et al., 2012).”
BackgroundEmbryonic stem (ES) cell‐derived cardiomyocytes: A good candidate for cell therapy applications
Pal, R. (2008) · Cell Biology International · doi:10.1016/j.cellbi.2008.12.001 · Cited by 28
Use of stem cells for the treatment of multiple sclerosis
Karussis, D. M., & Kassis, I. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.9.1189 · Cited by 23
Natural Killer Cell Subsets Differentially Reject Embryonic Stem Cells Based on Licensing
Perez-Cunningham, J., Ames, E., Smith, R. C., Peter, A. K., Naidu, R., Nolta, J. A., & Murphy, W. J. (2014) · Transplantation · doi:10.1097/tp.0000000000000063 · Cited by 24
“A previous report suggested that T cells alone, rather than NK cells, were solely responsible for the rejection of ESC (7).”
BackgroundStem cell‐based treatment in geographic atrophy: promises and pitfalls
Kvanta, A., & Pechhacker, M. K. G. (2013) · Acta Ophthalmologica · doi:10.1111/aos.12185 · Cited by 23
“Also, subretinal transplantation of RPE-choroid sheets was not superior to RPE in suspension and resulted in more postoperative complications in a randomized trial (Falkner-Radler et al. 2011).”
BackgroundГордеева, О. Ф., & Nikonova, T. M. (2013) · Cell Transplantation · doi:10.3727/096368912x657837 · Cited by 25
Concise review: current trends on applications of stem cells in diabetic nephropathy
Liu, D., Zheng, W., Pan, S., & Liu, Z. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03206-1 · Cited by 23
Rogers, S. A., Chen, F., Talcott, M., Liapis, H., & Hammerman, M. R. (2006) · Transplant Immunology · doi:10.1016/j.trim.2006.08.007 · Cited by 23
Han, L., Shao, J., Su, L., Gao, J., Wang, S., Zhang, Y. L., Zhang, S., Zhao, B., & Miao, J. (2012) · Stem Cells and Development · doi:10.1089/scd.2012.0055 · Cited by 21
“Embryonic stem cells (ESCs) have been proposed as a preferable source of endothelial cells due to their low immunogenic profile and high proliferative potential [3].”
Immune response to stem cells and strategies to induce tolerance
Batten, P., Rosenthal, N. A., & Yacoub, M. H. (2007) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2007.2120 · Cited by 23
“…involvement of critical factors in cardiomyocyte differentiation, including bone morphogenic protein (Bin et al. 2006) and Wnt signalling proteins (Eisenberg & Eisenberg 1999; Pandur et al. 2002; Terami et al. 2004), and such factors have the potential to improve the efficiency of stem cell…”
BackgroundJi, X., Zhou, Y., Gao, Q., He, H., Wu, Z., Feng, B., Mei, Y., Cheng, Y., Zhou, W., Chen, Y., et al. (2022) · Brain · doi:10.1093/brain/awac358 · Cited by 21
“From a clinical perspective, hESCs and their differentiated derivatives express low levels of HLA molecules, 48,49 the major determinant of immunogenicity in stem cell therapy, suggesting probably minor immune response after cell transplantation in vivo .”
Reprogramming of the MHC‐I and Its Regulation by NFκB in Human‐Induced Pluripotent Stem Cells
Pick, M., Ronen, D., Yanuka, O., & Benvenisty, N. (2012) · Stem Cells · doi:10.1002/stem.1242 · Cited by 22
Self-citationSchmitt, J., Eckardt, S., Schlegel, P. G., Sirén, A., Bruttel, V. S., McLaughlin, K. J., Wischhusen, J., & Müller, A. M. (2015) · Molecular Medicine · doi:10.2119/molmed.2014.00188 · Cited by 21
“In vivo analyses further showed that xeno-rejection of hESCs and of hESCderived cells is mainly T cell–mediated and that NK cells also are involved (21,22).”
BackgroundImmunological considerations for cell therapy using human embryonic stem cell derivatives
Drukker, M. (2008) · StemBook · doi:10.3824/stembook.1.14.1 · Cited by 19
“Furthermore, MHC-I expression levels reached somatic levels on 3 stembook.org IFN-γ treated teratoma cells (Drukker et al., 2002).”
BackgroundSelf-citationPluripotent stem cells as new drugs? The example of Parkinson's disease
Preynat‐Seauve, O., Burkhard, P. R., Villard, J., Zingg, W., Ginovart, N., Féki, A., Dubois‐Dauphin, M., Hurst, S., Mauron, A., Jaconi, M. E., et al. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.03.003 · Cited by 19
Metadata
- Authors
- Drukker, M., Katchman, H., Katz, G., Even-Tov Friedman, S., Shezen, E., Hornstein, E., Mandelboim, O., Reisner, Y., & Benvenisty, N.
- Affiliations
- Hebrew University of Jerusalem (IL)
- Weizmann Institute of Science (IL)
- Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
- Corresponding author
- Drukker, Micha
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-08-18
- Volume
- 24
- Issue
- 2
- Pages
- 221-229
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W2006712783
- Cited by
- 402
- References
- 49
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 6 · 2023: 6 · 2022: 6 · 2021: 9 · 2020: 11 · 2019: 12 · 2018: 16 · 2017: 15 · 2016: 12 · 2015: 21 · 2014: 19 · 2013: 30 · 2012: 34
- FWCI
- 14.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Stem Cells (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion)
- Funders
- Israel Science Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Surgery › Xenotransplantation and immune response
- Health Sciences › Medicine › Transplantation › Organ and Tissue Transplantation Research
- Keywords
- human embryonic stem cells, immune rejection, xenotransplantation, allorejection, T cell response, cytotoxic T lymphocytes, MHC class I, immunodeficient mice, immunocompetent mice, cell therapy, immunosuppression
- MeSH terms
- Animals, Cell Differentiation, Embryo, Mammalian, Graft Rejection, Humans, Immunocompetence, Membrane Glycoproteins, Mice, Inbred Strains, Mice, Mutant Strains, Stem Cells, T-Lymphocytes, Cytotoxic, Transplantation, Heterologous, T-Lymphocyte Subsets, Mice, SCID, Gene Expression Profiling, Stem Cell Transplantation, Tumor Necrosis Factors, Mice, Fas Ligand Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.